Welcome to our dedicated page for Inspira Technologies Oxy Bhn SEC filings (Ticker: IINN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inspira Technologies Oxy B.H.N. Ltd. filings document foreign-private-issuer current reports, shareholder meeting materials and registration statement incorporation for its technology business. Form 6-K reports furnish press releases on AME system orders, commercial deployments, the QTREX platform, cryogenic interconnect development and shareholder communications, while proxy materials cover voting matters such as amendments to the company's articles of association.
Other filings describe governance and officer appointments, ordinary-share voting procedures, Form F-3 and Form S-8 registration statement references, and capital-structure context tied to the company's Nasdaq-listed securities and medical technology operations.
Inspira Technologies Oxy B.H.N. Ltd. filed a report noting it has increased the maximum aggregate offering price of its ordinary shares that may be issued under its existing Sales Agreement with A.G.P./Alliance Global Partners from $7,117,720 to $9,985,579. This agreement allows the company to sell ordinary shares from time to time, and the change expands the total dollar amount of shares that can be issued through this program.
The company also filed a legal opinion from Sullivan & Worcester Tel-Aviv (Har-Even & Co.) confirming the legality of issuing and selling these ordinary shares under the Sales Agreement. This report is incorporated by reference into multiple existing registration statements on Form F-3 and Form S-8, meaning those registration statements now include this updated at-the-market capacity.